MRP2 haplotypes confer differential susceptibility to toxic liver injury
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Multidrug resistance protein 2 (MRP2, ABCC2) plays an important role in the biliary clearance of a wide variety of endogenous and exogenous toxic compounds. Therefore, polymorphisms and mutations in the MRP2 gene may affect individual susceptibility to hepatotoxic reactions. METHODS: Associations between genetic variations of MRP2 and toxic hepatitis were investigated using integrated population genetic analysis and functional molecular studies. RESULTS: Using a gene scanning method, 12 polymorphisms and mutations were found in the MRP2 gene in a Korean population. Individual variation at these sites was analyzed by conventional DNA screening in 110 control subjects and 94 patients with toxic hepatitis induced mostly by herbal remedies. When haplotypes were identified, over 85% of haploid genes belonged to the five most common haplotypes. Among these, a haplotype containing the g.-1774delG polymorphism showed a strong association with cholestatic or mixed-type hepatitis, and a haplotype containing the g.-1549G>A, g.-24C>T, c.334-49C>T, and c.3972C>T variations was associated with hepatocellular-type hepatitis. A comprehensive functional study of these sites revealed that genetic variations in the promoter of this gene are primarily responsible for the susceptibility to toxic liver injuries. The g.-1774delG variation and the combined variation of g.-1549G>A and g.-24C>T decreased MRP2 promoter activity by 36 and 39%, respectively. In addition, the promoter carrying the g.-1774delG allele showed a defect in the bile acid-induced induction of promoter activity. CONCLUSIONS: These results suggest that genetic variations of MRP2 are an important predisposing factor for herbal-induced or drug-induced toxic liver injuries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355
Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K., & Spielberg, S. P. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.3 · Cited by 213
Geier, A., Dietrich, C. G., Grote, T., Beuers, U., Prüfer, T., Fraunberger, P., Matern, S., Gartung, C., Gerbes, A. L., & Bilzer, M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.031 · Cited by 66
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
“Variants of this transporter have been associated with DILI.(164,165) When BSEP function is impaired, basolateral efflux systems (MRP3 and MRP4) are potential salvage systems to lower the burden of bile salts and drug metabolites for hepatocytes.”
BackgroundAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport
Corsini, A., & Bortolini, M. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.23 · Cited by 173
Genetic risk factors in the development of idiosyncratic drug-induced liver injury
Stephens, C., Lucena, M. I., & Andrade, R. J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1854726 · Cited by 32
Koide, E., Pietz, H. L., Beltran, J., & Chen, J. (2025) · Nature Communications · doi:10.1038/s41467-024-55810-w · Cited by 17
Koide, E., Pietz, H. L., Beltran, J., & Chen, J. (2024) · doi:10.1101/2024.06.24.600277 · Cited by 17
“The inward-swing of the NBDs originates at the substrate-binding site, where TM helix 6, 8, 16, and 17 move towards each other and the side chains of F591 and W1254 reposition to contact LTC 4 (Fig.”
Metadata
- Authors
- Choi, J. H., Ahn, B. M., Yi, J., Lee, J. H., Lee, J. H., Nam, S. W., Chon, C. Y., Han, K.-H., Ahn, S. H., Jang, I.-J., Cho, J.-Y., Suh, Y., Cho, M.-O., Lee, J.-E., Kim, K. H., & Lee, M. G.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2007-06
- Volume
- 17
- Issue
- 6
- Pages
- 403-415
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2092375748
- Cited by
- 138
- References
- 7
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.